A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function
J3L-MC-EZEH
Phase 1 other active
Quick answer
A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function for Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment
- Phase
- Phase 1
- Modality
- other
- Status
- active